US President Donald Trump has increased the tension of companies after taking decisions in quick succession. Donald Trump has decided to increase many types of tariffs. Also, he has indicated that the US can impose many more tariffs on imports. Because he has given many types of threats. Experts say that these decisions can have an impact on pharma and metal companies. Tariff war can also start on computers, chips, semiconductors. 25, 50 or 100% tariff can be imposed on imported chips.

Trump's threatening statement - To avoid tariffs and taxes, production will have to be done in the US itself
Trump has also asked to set up plants in the US.

But it has spoiled the health of pharma companies - Nifty Pharma has fallen sharply. On Tuesday, 28 January 2025, the pharma index fell by more than 2 percent. It has fallen by -5 percent in a week. It has fallen by -11 percent in a month.

Tariff imposed in the US...
Zydus Life
Sun Pharma
Lupin
DRL
Divi's Lab Company will be affected.

The fall in shares is not stopping

Zydus Life -32%
Piramal Pharma -30%
Arvindo Pharma -27% Glenmark -25% Syngene -22% Cipla -19% Laurus Lab -18% DRL -17% Lupin -16% Sun Pharma -13% Divi's Lab -12% Torrent Pharma -8% They have fallen. What is happening with pharma companies?  During Donald Trump's presidency, the impact of many decisions was seen on US pharma companies and the global pharma industry. His administration took several steps aimed at controlling prices in the US pharmaceutical industry and improving the health care system. Let's understand these decisions and their impact: 1. Drug price control: - Trump planned to implement the "Most Favored Nation" rule to stop the rising prices of medicines, under which the price of medicines in the US was to be equal to the lowest prices in other countries. This decision was challenging for US pharma companies, as it affected their ability to profit. Impact: - The reduction in drug prices brought relief to US healthcare consumers. However, the profit margins of pharma companies were affected, especially those companies that were selling medicines at high prices in the US market. 2. Promotion of generic medicines: - The Trump administration supported the FDA (Food and Drug Administration) to speed up the approval of new generic drugs. The purpose of this was to have more competition and reduce the prices of medicines. Impact:- Indian generic drug companies benefited because they provide quality medicines at low prices. This was a challenge for American pharma companies dependent on branded drugs. 3. Drug re-importation:- Trump proposed to allow American citizens to import cheap medicines from countries like Canada. This move was to increase pressure on American companies to reduce drug prices. Impact:- American drug companies faced pressure on prices. Changes were seen in the strategy and lobbying of pharma companies. 4. Changes in the Affordable Care Act (ACA).